Researchers use data to identify different forms of prostate cancers and effective treatment options

Published on May 24, 2013 at 5:09 AM · No Comments

Some prostate cancer patients unnecessarily undergo surgery or harsh treatments because science fails to identify the differences between slow-growing and aggressive forms of the disease. Researchers at Case Western Reserve University and Johns Hopkins Medical Institutes are developing technology that allows patients to safely choose to do nothing, opt for relatively mild treatments or take drastic measures.

The project is one of several Anant Madabhushi, an associate professor of biomedical engineering at Case Western Reserve and director of the Center for Computational Imaging and Personalized Diagnostics, is involved in.

Madabhushi brought the center and a dozen researchers to Case Western Reserve from Rutgers University this academic year. The center's overall mission is to develop the new science of using big data to identify different forms of diseases and the most effective treatments.

"The data does exist," Madabhushi said. "If someone has a disease, we can detect it. The issue is what to do next. We're detecting half-a-million cases of breast and prostate cancers each year. How do you treat them? What are the options? What is the right treatment?"

Madabhushi and Robert Veltri, an associate professor of urology at Johns Hopkins, have won a three-year, $1.2 million Department of Defense grant to develop a guide to steer prostate cancer patients to the most effective treatment.

The medical community estimates 241,740 prostate cancer cases were diagnosed nationally last year, and the number is expected to grow annually as the population ages and detection improves.

The researchers are concentrating on identifying the 15 percent of prostate cancers considered very low-risk. Sufferers are likely to survive 20 years, depending on the treatment they receive.

"We don't want to expose someone to a therapy that won't work for him," Madabhushi said.

Not only may patients suffer unnecessarily, the costs can be astronomical. For example, radiation therapy always destroys healthy tissue. Rectal toxicity can be caused by radiation spillover from prostate treatment, he explained. Use of a proton gun to treat prostate cancer reaches about $125,000 per patient.

In their search for cues that help identify very low-risk prostate cancer and the best treatments for each form, the researchers are looking at data from 300 men, half who chose immediate surgery after diagnosis and half who chose to have their cancer monitored.

Researchers at Johns Hopkins are focusing on molecular biomarkers from tissue samples of prostate cancers. They are looking at a set of five unique biomarkers to separate the very low-risk group from the low-risk, intermediate-risk and high-risk groups.

The Case Western Reserve researchers are undertaking a quantitative computerized image analysis-based study of the organization and structure of diseased tissues. Specifically, they are looking for differences in the shape and size and architecture of nuclei within the tissue, as well as the shape of the cross-sections of glands in the samples. All can indicate the disease's aggressiveness and characteristics.

The data comes from digitized images of biopsy slides. A simple biopsy image of prostate cancer digitized via a whole slide scanner can be several gigabytes in size. In a typical biopsy procedure, 10 to 12 samples are removed and, after those are laid out on slides and digitized, that translates to hundreds of gigabytes of data.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post